Sumary of Inequities in health outcomes prompt renewed calls for change:
- Fatima Cody Stanford, MD, MPH, MPA, FAAP, FACP, FAHA, FTOS, an obesity medicine physician scientist at Massachusetts General Hospital and Harvard Medical School, told Endocrine Today..
- Uché Blackstock, MD, founder and CEO of Advancing Health Equity and former associate professor of emergency medicine at the New York University School of Medicine, told Endocrine Today..
- Eugenics theory, defining certain races and ethnicities as biologically inferior, and experimentation on enslaved and other vulnerable groups without their consent, led many Black Americans to distrust the medical establishment and resulted in health care provider bias toward Black patients, Golden said..
- Historically, a lack of Black physicians due to the closure of medical schools that trained Black students in 1910, following publication of the Flexner Report on medical education in the U.S., left only two institutions training Black physicians at a time when they could not gain access to predominantly white medical schools due to discrimination..
- “Too often, for chronic medical problems like diabetes, we’re taught as educators and clinicians that it is due to individual choices,”.
- LeRoy, also associate dean for student affairs and admission at Wright State University Boonshoft School of Medicine in Dayton, Ohio, told Endocrine Today..
- Joseph, MD, MPH, FAHA, assistant professor of medicine in the division of endocrinology, diabetes and metabolism at The Ohio State University Wexner Medical Center, said clinicians should keep three key goals in mind to reach patients..
- “Endocrinologists and obesity medicine specialists can also engage in and promote academic-community partnerships to deliver health care needs to communities where trust with the medical establishment has been compromised,”.
- Mishriky, MD, assistant professor in the department of internal medicine at the Brody School of Medicine at East Carolina University, and colleagues, compared SGLT2 inhibitors, GLP-1 receptor agonists and DPP-IV inhibitors with placebo for adults with type 2 diabetes across 11 cardiovascular outcomes trials assessing three- or four-point major adverse cardiac events..
- Pooled results showed no significant difference in the incidence of major adverse CV events among the three classes of diabetes medications vs…